Exploring the damage of mtDNA

# # # #

Mitochondria are curious little structures that live symbiotically within cells. They are believed to derive from an ancient bacterial past, and they still retain elements of that forgotten occupation: They have their own DNA.

Given that mitochondria are very metabolically active, that mitochondrial DNA can be vulnerable to damage.

Recently, researchers have proposed that damage to mitochondrial DNA might be a useful biomarker for Parkinson’s.

In today’s post, we will look at what mitochondria do, what damage to their DNA means, and how this could be very useful for our understanding of Parkinson’s.

# # # #


Source: Szegedify

In Chinese culture, 2023 has been in the Year of the Rabbit.

The Rabbit is a symbol of longevity, peace and prosperity. As such, 2023 is predicted to be a year of hope.

Here at SoPD HQ, we think 2023 has been the Year of the Biomarker.

Think about it. Over the course of this year, we have covered a couple of new reports proposing the alpha synuclein seeding assay (Click here to read more about this) and DOPA decarboxylase levels in cerebrospinal fluid as potentially useful markers for Parkinson’s (Click here to read more about this).

And recently, researchers have proposed another biomarker which involves an important aspect of Parkinson’s associated biology: Mitochondria.

Remind me: What are mitochondria?

Continue reading “Exploring the damage of mtDNA”

Inhibiting LRRK2: The Denali Phase I results

Denali

This week Denali Therapeutics released the results of a phase I clinical trial of their primary product, called DNL-201.

DNL-201 is a LRRK2 inhibitor that the company is attempting to take to the clinic for Parkinson’s disease. 

In today’s post we will look at what LRRK2 is, how an inhibitor might help in Parkinson’s, and what the results of the trial actually mean.


Wonder_Lake_and_Denali

Denali. Source: Wikipedia

Denali (Koyukon for “the high one”; also known as Mount McKinley) in Alaska is the highest mountain peak in North America, with a summit elevation of 20,310 feet (6,190 m) above sea level. The first verified ascent to Denali’s summit occurred on June 7, 1913, by four climbers Hudson Stuck, Harry Karstens, Walter Harper, and Robert Tatum.

Tatum (left), Karstens (middle), and Harper (right). Source: Gutenberg

Robert Tatum later commented, “The view from the top of Mount McKinley is like looking out the windows of Heaven!”

More recently another adventurous group associated with ‘Denali’ have been trying to scale lofty heights, but of a completely different sort from the mountaineering kind.

Continue reading “Inhibiting LRRK2: The Denali Phase I results”